Page last updated: 2024-11-06

9-anthraldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

9-Anthraldehyde is a versatile building block in organic synthesis. It is known for its ability to undergo various reactions, including aldol condensations, Wittig reactions, and Diels-Alder reactions. Its synthesis involves the oxidation of 9-anthracenemethanol, typically using oxidizing agents such as chromium trioxide or manganese dioxide. 9-Anthraldehyde has been extensively studied for its potential applications in the development of organic materials, such as fluorescent dyes, organic semiconductors, and liquid crystals. The compound exhibits strong fluorescence and has been investigated for its potential as a probe molecule in fluorescence microscopy. Its photophysical properties and ability to undergo photochemical reactions have also attracted interest in the field of photochemistry.'

Cross-References

ID SourceID
PubMed CID69504
CHEMBL ID4447118
SCHEMBL ID342278
MeSH IDM0197650

Synonyms (51)

Synonym
AC-13621
9-anthracene aldehyde
nsc15
9-anthrylcarboxaldehyde
nsc-15
9-formylanthracene
9-anthrylaldehyde
9-anthracenecarboxaldehyde
642-31-9
9-anthraldehyde ,
9-anthracenecarboxaldehyde, 97%
einecs 211-383-0
ccris 3165
anthracene-9-carbaldehyde
nsc 15
STK400294
A0779
AKOS000118906
ymnkuhivvmfofo-uhfffaoysa-
inchi=1/c15h10o/c16-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)15/h1-10h
A8813
unii-353s277yhy
ec 211-383-0
353s277yhy ,
FT-0621623
BBL023574
SCHEMBL342278
anthracene-9-carboxaldehyde
anthracene-9-aldehyde
9-anthracenaldehyde
9-anthracenecarbaldehyde
DTXSID9060940
9-anthracenecarbaldehyde #
J-100028
mfcd00001254
SR-01000313897-1
sr-01000313897
CHEMBL4447118
F19700
CS-W015320
SY033919
F3099-5689
Z57127521
AS-10816
Q63396302
AMY11196
EN300-18031
9-anthracenealdehyde
antracene-9-carboxaldehyde
SB66640
9-anthracenemethanal
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1602658Inhibition of mouse GAT-1 assessed as percentage of remaining specific binding of NO711 at 1 uM after 4 hrs by LC-ESI-MS/ms analysis relative to control2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Screening oxime libraries by means of mass spectrometry (MS) binding assays: Identification of new highly potent inhibitors to optimized inhibitors γ-aminobutyric acid transporter 1.
AID1544945Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as residual binding at 1 uM incubated for 4 hrs in presence of NO711 by LC-ESI-MS/MS analysis relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.88)18.7374
1990's4 (23.53)18.2507
2000's4 (23.53)29.6817
2010's8 (47.06)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.39 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index66.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]